Ten years ago “Spygate’’ consumed the NFL with a news cycle it wished never got started. It wrecked relationships, cost the Patriots draft picks and money, and forever tarnished the reputation of the franchise and its Hall of Fame-bound head coach, Bill Belichick. Eric Mangini, then the Jets coach, blew the whistle on the Patriots...
NYS Entity Status
- Surrender of Authority (Jul 03, 2014)
NYS Filing Date
JANUARY 09, 2013
NYS DOS ID#
NYS Entity Type
FOREIGN BUSINESS CORPORATION
2013 - BAKER/WOHL ARCHITECTS, INC.
AROUND THE WEB
- Recalling Spygate wreckage, the original NY-Boston scandal
By Mark Cannizzaro - Wednesday Sep 6, 2017
- Foes of Obama-Era Rule Work to Undo Birth Control Mandate
By ROBERT PEAR - Monday Jul 10, 2017
A lawyer and an epidemiologist who fought against the Affordable Care Act’s rule on contraception coverage from the outside are now the architects of the president’s reversal.
- Ryder Trucks Launches Campaign With 'Inc.'
Tuesday Sep 19, 2017
"The campaign underscores how truck owners are essentially dumping cash all over America's highways from all the hidden costs required in maintaining a private fleet," Ryder's Karen Jones tells"Marketing Daily."
- NY AG presses TransUnion, Experian for cybersecurity details
By DAVID KLEPPER, Associated Press - Tuesday Sep 19, 2017
ALBANY, N.Y. (AP) — New York Attorney General Eric Schneiderman is pressing TransUnion and Experian to explain what cybersecurity they have in place to protect sensitive consumer information following a recent breach at Equifax that exposed the data of 143 million Americans.In letters to executives at the two credit monitoring companies, the Democratic attorney general asked them to describe their existing security systems as well as what changes they've made since the Equifax cyberattack."The unprecedented data breach experienced by Equifax Inc.
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]